PharmAthene, Inc., a biodefense company, develops and commercializes medical counter measures against biological and chemical threats in the United States. The company focuses on developing lyophilized anthrax vaccines based on DepoVax, a proprietary technology platform that contributes recombinant protective antigen bulk drug substance. It serves National Institute of Allergy and Infectious Diseases, and the Biomedical Advanced Research and Development Authority. The company has a license agreement with ImmunoVaccine Technologies for the use of the DepoVax vaccine platform to develop an anthrax vaccine. PharmAthene, Inc. is headquartered in Annapolis, Maryland.
Hey @Tiptopptrader, Ive been watching PIP since November and they have a special dividend getting ready to be paid out. http://www.streetinsider.com/Divide...Declares+$2.91+Special+Dividend/12263431.html I would suggest looking this over before jumping in as this will have a substantial impact on the pps in the next few weeks
Thanks for the heads up @twerpner! Something don't smell right the divi is not that far from the pps. A red flag indeed